US 12,296,010 B2
Methods for isolating, culturing, and genetically engineering immune cell populations for adoptive therapy
Chris Ramsborg, Seattle, WA (US); Mark L. Bonyhadi, Sammamish, WA (US); Calvin Chan, Seattle, WA (US); and Pascal Beauchesne, Seattle, WA (US)
Assigned to Juno Therapeutics, Inc., Seattle, WA (US)
Filed by Juno Therapeutics, Inc., Seattle, WA (US)
Filed on Dec. 16, 2024, as Appl. No. 18/983,137.
Application 18/983,137 is a continuation of application No. 18/166,447, filed on Feb. 8, 2023, granted, now 12,208,137.
Application 18/166,447 is a continuation of application No. 17/850,875, filed on Jun. 27, 2022.
Application 17/850,875 is a continuation of application No. 15/305,337, granted, now 11,400,115, issued on Aug. 2, 2022, previously published as PCT/US2015/027401, filed on Apr. 23, 2015.
Claims priority of provisional application 61/983,415, filed on Apr. 23, 2014.
Prior Publication US 2025/0121062 A1, Apr. 17, 2025
This patent is subject to a terminal disclaimer.
Int. Cl. A61K 40/31 (2025.01); A61K 35/12 (2015.01); A61K 40/11 (2025.01); A61K 40/42 (2025.01); C12N 5/0783 (2010.01); C12N 5/10 (2006.01)
CPC A61K 40/31 (2025.01) [A61K 40/11 (2025.01); A61K 40/42 (2025.01); A61K 40/4211 (2025.01); C12N 5/0636 (2013.01); C12N 5/10 (2013.01); A61K 2035/124 (2013.01)] 20 Claims
 
1. A method of treating systemic lupus erythematosus (SLE) in a human subject, the method comprising intravenously administering a dose of genetically engineered CD4+ and CD8+ T cells to a human subject with SLE, wherein:
the CD4+ and CD8+ T cells of the dose are at a ratio, wherein the ratio is between at or about 5:1 and at or about 1:3;
the dose of genetically engineered CD4+ and CD8+ T cells is between at or about 5×106 to 500×106 cells; and
the CD4+ and CD8+ T cells are genetically engineered with a chimeric antigen receptor (CAR), wherein the CAR comprises an scFv that binds CD19, a transmembrane domain, and an intracellular signaling domain comprising a 4-1BB costimulatory signaling domain and a CD3zeta signaling domain.